Lonza Expands Singapore Bioservices
News Jun 13, 2011
Lonza is investing nearly $12 million to expand its biopharmaceutical development services in Singapore. Lonza’s Development Services business provides customized services for the development of robust biomanufacturing processes.
The expansion will add 1,858 m² of lab space and associated equipment, and will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Lonza currently offers these services in its Slough, UK facility with a limited offering in Singapore. The facility is expected to come on-line in by mid-2012.
“This further investment in our Singapore location is driven by the increased demand we are seeing on a global basis,” said Janet White, head of development services at Lonza.
“We are looking forward to offering the full range of our GS Gene Expression System and other technologies in Asia. The location is advantageous to many of our customers from across the globe, and in particular, with our growing set of customers based in the region.”
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018